ART Advanced Research Technologies Ships First of Two Optix Systems to U.S. National Cancer Institute
September 17 2008 - 9:13AM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
announced today that it has shipped the first of two Optix� MX2
units ordered by the National Cancer Institute - Frederick
(NCI-Frederick), in Maryland, USA.
"We are very proud to see that the NCI has chosen our Optix
molecular imaging systems to conduct its world-class research and
to have them among our growing base of clients," said Sebastien
Gignac, Chairman & CEO of ART. "The fact that the NCI has
ordered two Optix systems in succession is testimony to the power
of our technology to address the needs of leading researchers in
the field of oncology", added Mr. Gignac.
One of two NCI campuses, NCI-Frederick is located in Maryland
and is devoted solely to biomedical research. Through its many
advanced technologies, NCI-Frederick strives to speed the
translation of laboratory discoveries into therapies for
patients.
About the Optix� system
Based on time-domain technology, which allows measurement of the
light's time of arrival, the Optix� in vivo optical molecular
imaging device is the most sensitive optical imager commercially
available on the preclinical market, allowing for detection of
lower concentrations of signals deeper inside the body. Unique to
the Optix system is the ability to recover fluorescence lifetime,
which can be used to separate and quantify probe distributions
depending on their respective biochemical environment. Also part of
the Optix product offering is a CT fusion software package allowing
researchers to export the scan obtained using Optix in DICOM
format, and fuse it with microCT for a full 3D anatomical
reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra�
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
About NCI
The National Cancer Institute (NCI) is a component of the
National Institutes of Health (NIH), one of eight agencies that
compose the Public Health Service (PHS) in the Department of Health
and Human Services (DHHS). The NCI, established under the National
Cancer Institute Act of 1937, is the Federal Government's principal
agency for cancer research and training. NCI leads the National
Cancer Program and the NIH effort to dramatically reduce the burden
of cancer and improve the lives of cancer patients and their
families, through research into prevention and cancer biology, the
development of new interventions, and the training and mentoring of
new researchers. For more information, please visit the NCI Web
site at http://www.cancer.gov.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in ART's most recent Annual Information
Form and the financial statements for the year ended December 31,
2007, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer jbedard@art.ca ART Advanced Research
Technologies Inc. Dino DiCamillo Vice President of Global Sales and
Marketing, Preclinical Imaging 514-832-0777 ddicamil@art.ca /
www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024